Vmbook Online ordering

Dynavax Technologies Corporati

Dynavax Technologies Corporation (DVAX) is a publicly traded biopharmaceutical company based in the United States. The company is focused on the development and commercialization of novel vaccines designed to prevent or treat infectious diseases and address unmet medical needs.

In terms of financials, here are some key points to consider:

* Revenue: DVAX reported revenue of $128.3 million in 2020, up from $53.7 million in 2019. The majority of the company's revenue comes from sales of its hepatitis B vaccine, Heplisav-B.

* Net Income: DVAX recorded a net loss of $41.9 million in 2020, compared to a net loss of $52.6 million in 2019.

* Earnings Per Share (EPS): DVAX reported a loss per share of $0.37 in 2020, compared to a loss per share of $0.53 in 2019.

In terms of growth, DVAX has seen significant revenue growth in recent years, driven by the successful launch of Heplisav-B. However, the company has yet to turn a profit, as it continues to invest in research and development activities.

DVAX has a market capitalization of around $1.8 billion as of March 2023, making it a mid-cap stock. The stock is listed on the NASDAQ stock exchange and is considered a high-risk/high-reward investment due to the company's focus on developing novel vaccines, which can be difficult to bring to market.

It's worth noting that investing in individual stocks, including Dynavax, always carries risk, and it's important to do thorough research and consider seeking advice from a financial advisor before making any investment decisions.